The 2nd CrownBio Symposium of Biomedical Sciences - Frontiers in Cancer Drug Discovery

Wednesday June 19th, 2019 - Parkyard Hotel, Zhangjiang, Shanghai

Parkyard Hotel, Zhangjiang, ShanghaiJoin our second biomedical science symposium, focusing on the latest advances in oncology drug discovery.

Oncology and immuno-oncology innovations are continuing to progress at a rapid rate. To ensure this innovation continues, and that new therapies are robust and effective before entering the clinic, preclinical models and methods need to be continually enhanced and developed. By combining novel therapeutic approaches and improved technologies we can continue to revolutionize treatment regimens and improve patient outcomes.

The symposium will bring together R&D and preclinical teams from biotechnology and pharmaceutical companies to facilitate cross discipline discussions on current techniques, and how you can move forward with future approaches.

Discussion Topics Include

  • How novel platforms such as organoids enhance oncology drug development programs
  • The latest advances in in vivo cancer modeling and oncology/immuno-oncology models
  • How to overcome challenges in expanding China biotech to a global market

Presentation & Speakers

Dr. Henry Li

CSO, Crown Bioscience Inc.
Modeling human cancers - Building the world's largest patient-derived library of patient-derived organoids (PDO)/patient-derived xenografts (PDX) for translational oncology research

Min Huang

Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Metabolic heterogeneity and cancer therapy

Dr. Ruilin Sun

Shanghai Model Organisms Center, Inc.
Immune checkpoint humanized models and their use in immuno-oncology studies

Long Cui

Xinhua Hospital affiliated to Shanghai Jiao Tong University
Integration of clinical resource and translational research for developing combination therapy for colorectal cancer: Bortezomib as a sensitizer for new targeted drugs

Dr. Yangzhou Wang

COO, Crown Bioscience Inc.
JSR Life Sciences integrated oncology platform for biomarker-CDx Development

Joan Shen MD, PhD

Head of Research and Development, I-Mab Biopharma Co., Ltd
The challenges - China biotech going global

Bin Shi

CSO, Zhejiang Deuracor Inc.
Anti-tumor therapeutic innovation: from an in vivo pharmacology perspective

Dr.Qun Dang

Vice President, Global Head of BD and External Innovation, PR&D, Qilu Pharmaceutical, China
Some personal experience in the research and development of new drugs in the field of Cancer

Attendance is free, but seats are limited, reserve your space by submitting the registration form today!

Register Now!

Register Now

Your privacy is important to us.
We'll never share your information.